307 related articles for article (PubMed ID: 26867766)
21. Enhanced antitumor effects of the BRBP1 compound peptide BRBP1-TAT-KLA on human brain metastatic breast cancer.
Fu B; Long W; Zhang Y; Zhang A; Miao F; Shen Y; Pan N; Gan G; Nie F; He Y; Zhang J; Teng G
Sci Rep; 2015 Jan; 5():8029. PubMed ID: 25619721
[TBL] [Abstract][Full Text] [Related]
22. Zerumbone Induces Apoptosis in Breast Cancer Cells by Targeting αvβ3 Integrin upon Co-Administration with TP5-iRGD Peptide.
E M Eid E; S Alanazi A; Koosha S; A Alrasheedy A; Azam F; M Taban I; Khalilullah H; Sadiq Al-Qubaisi M; A Alshawsh M
Molecules; 2019 Jul; 24(14):. PubMed ID: 31337024
[TBL] [Abstract][Full Text] [Related]
23. Modification of IL-24 by tumor penetrating peptide iRGD enhanced its antitumor efficacy against non-small cell lung cancer.
Yang J; Yang J; Wei Y; Yin H; Fang L; Chai D; Li H; Li H; Zhang Q; Zheng J
Int Immunopharmacol; 2019 May; 70():125-134. PubMed ID: 30798161
[TBL] [Abstract][Full Text] [Related]
24. Superior intratumoral penetration of paclitaxel nanodots strengthens tumor restriction and metastasis prevention.
Ni D; Ding H; Liu S; Yue H; Bao Y; Wang Z; Su Z; Wei W; Ma G
Small; 2015 Jun; 11(21):2518-26. PubMed ID: 25678130
[TBL] [Abstract][Full Text] [Related]
25. The influence of the penetrating peptide iRGD on the effect of paclitaxel-loaded MT1-AF7p-conjugated nanoparticles on glioma cells.
Gu G; Gao X; Hu Q; Kang T; Liu Z; Jiang M; Miao D; Song Q; Yao L; Tu Y; Pang Z; Chen H; Jiang X; Chen J
Biomaterials; 2013 Jul; 34(21):5138-48. PubMed ID: 23582684
[TBL] [Abstract][Full Text] [Related]
26. Shrapnel nanoparticles loading docetaxel inhibit metastasis and growth of breast cancer.
Xu P; Meng Q; Sun H; Yin Q; Yu H; Zhang Z; Cao M; Zhang Y; Li Y
Biomaterials; 2015 Sep; 64():10-20. PubMed ID: 26106797
[TBL] [Abstract][Full Text] [Related]
27. iRGD-functionalized PEGylated nanoparticles for enhanced colon tumor accumulation and targeted drug delivery.
Ma L; Chen Q; Ma P; Han MK; Xu Z; Kang Y; Xiao B; Merlin D
Nanomedicine (Lond); 2017 Aug; 12(16):1991-2006. PubMed ID: 28745123
[TBL] [Abstract][Full Text] [Related]
28. An iRGD peptide fused superantigen mutant induced tumor-targeting and T lymphocyte infiltrating in cancer immunotherapy.
Song Y; Xu M; Li Y; Li Y; Gu W; Halimu G; Fu X; Zhang H; Zhang C
Int J Pharm; 2020 Aug; 586():119498. PubMed ID: 32505575
[TBL] [Abstract][Full Text] [Related]
29. [Antitumor and antimetastatic effect of antimicrobial peptide conjugated with tumor homing peptide TMTP1 on the transplanted prostate cancer and gastric cancer in nude mice].
Ma XY; Li S; Luo DF; Liu RH; Lu YP; Wang SX; Ma D; Xi L
Zhonghua Zhong Liu Za Zhi; 2013 Oct; 35(10):737-41. PubMed ID: 24378093
[TBL] [Abstract][Full Text] [Related]
30. Co-administration of iRGD with peptide HPRP-A1 to improve anticancer activity and membrane penetrability.
Hu C; Chen X; Huang Y; Chen Y
Sci Rep; 2018 Feb; 8(1):2274. PubMed ID: 29396568
[TBL] [Abstract][Full Text] [Related]
31. iRGD-modified lipid-polymer hybrid nanoparticles loaded with isoliquiritigenin to enhance anti-breast cancer effect and tumor-targeting ability.
Gao F; Zhang J; Fu C; Xie X; Peng F; You J; Tang H; Wang Z; Li P; Chen J
Int J Nanomedicine; 2017; 12():4147-4162. PubMed ID: 28615942
[TBL] [Abstract][Full Text] [Related]
32. A modified thymosin alpha 1 inhibits the growth of breast cancer both in vitro and in vivo: suppressment of cell proliferation, inducible cell apoptosis and enhancement of targeted anticancer effects.
Lao X; Li B; Liu M; Shen C; Yu T; Gao X; Zheng H
Apoptosis; 2015 Oct; 20(10):1307-20. PubMed ID: 26283169
[TBL] [Abstract][Full Text] [Related]
33. Increased antitumor activity of tumor-specific peptide modified thymopentin.
Lao X; Li B; Liu M; Chen J; Gao X; Zheng H
Biochimie; 2014 Dec; 107 Pt B():277-85. PubMed ID: 25236717
[TBL] [Abstract][Full Text] [Related]
34. Tumor penetrability and anti-angiogenesis using iRGD-mediated delivery of doxorubicin-polymer conjugates.
Wang K; Zhang X; Liu Y; Liu C; Jiang B; Jiang Y
Biomaterials; 2014 Oct; 35(30):8735-47. PubMed ID: 25023394
[TBL] [Abstract][Full Text] [Related]
35. Does ligand-receptor mediated competitive effect or penetrating effect of iRGD peptide when co-administration with iRGD-modified SSL?
Zhang WQ; Yu KF; Zhong T; Luo LM; Du R; Ren W; Huang D; Song P; Li D; Zhao Y; Wang C; Zhang X
J Drug Target; 2015 Dec; 23(10):897-909. PubMed ID: 26087869
[TBL] [Abstract][Full Text] [Related]
36. Immunomodulatory and enhanced antitumor activity of a modified thymosin α1 in melanoma and lung cancer.
Wang F; Li B; Fu P; Li Q; Zheng H; Lao X
Int J Pharm; 2018 Aug; 547(1-2):611-620. PubMed ID: 29933059
[TBL] [Abstract][Full Text] [Related]
37. Activatable iRGD-based peptide monolith: Targeting, internalization, and fluorescence activation for precise tumor imaging.
Cho HJ; Lee SJ; Park SJ; Paik CH; Lee SM; Kim S; Lee YS
J Control Release; 2016 Sep; 237():177-184. PubMed ID: 27349354
[TBL] [Abstract][Full Text] [Related]
38. Tumor homing cell penetrating peptide decorated nanoparticles used for enhancing tumor targeting delivery and therapy.
Gao H; Zhang Q; Yang Y; Jiang X; He Q
Int J Pharm; 2015 Jan; 478(1):240-250. PubMed ID: 25448586
[TBL] [Abstract][Full Text] [Related]
39. Combination of NRP1-mediated iRGD with 5-fluorouracil suppresses proliferation, migration and invasion of gastric cancer cells.
Zhang L; Xing Y; Gao Q; Sun X; Zhang D; Cao G
Biomed Pharmacother; 2017 Sep; 93():1136-1143. PubMed ID: 28738522
[TBL] [Abstract][Full Text] [Related]
40. Nanoparticles coated with the tumor-penetrating peptide iRGD reduce experimental breast cancer metastasis in the brain.
Hamilton AM; Aidoudi-Ahmed S; Sharma S; Kotamraju VR; Foster PJ; Sugahara KN; Ruoslahti E; Rutt BK
J Mol Med (Berl); 2015 Sep; 93(9):991-1001. PubMed ID: 25869026
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
